Glycine zinc adjuvant and vaccine containing glycine zinc adjuvant

A technology of zinc glycinate and vaccine, applied in the field of immunology, can solve problems such as high price, toxic and side effects, and achieve the effects of low cost, small toxic and side effects, and enhancing humoral immune response

Active Publication Date: 2014-10-15
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In order to solve the problems of toxic and side effects and high price of existing vaccine adjuvants, the present inven

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glycine zinc adjuvant and vaccine containing glycine zinc adjuvant
  • Glycine zinc adjuvant and vaccine containing glycine zinc adjuvant
  • Glycine zinc adjuvant and vaccine containing glycine zinc adjuvant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] The Hepatitis A vaccine containing glycine zinc adjuvant provided in this example is: 0.1 mg glycinate zinc adjuvant is dissolved in PBS with pH = 6.5, and then mixed with each single portion of HAV antigen (that is, the single injection dose used in animal experiments) according to routine , to obtain hepatitis A vaccine containing zinc glycine adjuvant.

[0023] Wherein, zinc glycinate is commercially available product, is amino acid chelate, and molecular formula is , with a molecular weight of 213.5 and a zinc content of 29.0-30.6wt%, purchased from Shanghai Jinsui Biotechnology Co., Ltd.; HAV antigen is a commercially available 18EU HAV antigen solution with a titer of 256EU / ml, purchased from Peking Union Medical College, Chinese Academy of Medical Sciences Institute of Medical Biology.

[0024] The immune test and effect of the hepatitis A vaccine that embodiment 1 gained contains zinc glycine adjuvant are as follows:

[0025] A. Immunity

[0026] The 6-8 wee...

Embodiment 2

[0041] The Hepatitis A vaccine containing zinc glycinate adjuvant provided in this example is: 1 mg zinc glycinate is dissolved in PBS with pH=7.5, and then mixed with each single portion of HAV antigen (that is, the single injection dose used in animal experiments), Obtain the hepatitis A vaccine that contains glycine zinc adjuvant, wherein, glycine zinc, HAV antigen are with embodiment 1;

[0042] The immune test of the hepatitis A vaccine containing zinc glycine adjuvant obtained in this example is the same as that in Example 1, and the results are shown in Table 2.

[0043] Table 2 shows the serum anti-HAV IgG antibody levels of mice in each experimental group within 24 weeks after using the adjuvant provided in Example 2.

[0044] Table 2

[0045]

[0046]Through data analysis, it can be seen that from the 4th week after immunization, all experimental groups except the blank group can produce anti-HAV IgG antibodies, and generally reach the peak at the 16th week, and ...

Embodiment 3

[0048] The hepatitis B vaccine containing glycine zinc adjuvant provided in this example is: dissolve 0.5 mg of glycine zinc adjuvant in PBS with pH = 7.5, and then mix with each single portion of hepatitis B surface antigen (that is, the single injection dose used in animal experiments). Mix to obtain the hepatitis B vaccine containing zinc glycine adjuvant.

[0049] Among them, the zinc glycinate is the same as that in Example 1, and the hepatitis B surface antigen is a conventional commercial product containing 1 μg of hepatitis B surface antigen, purchased from the Institute of Medical Biology, Chinese Academy of Medical Sciences.

[0050] The immune test of the hepatitis B vaccine containing zinc glycine adjuvant obtained in this example is the same as that in Example 1, and the effects are shown in Table 3.

[0051] Table 3 shows the serum anti-HBsAg IgG antibody levels of mice in each experimental group after using the adjuvant provided in Example 3 within 24 weeks.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a glycine zinc adjuvant and a vaccine containing the glycine zinc adjuvant, and each part of the vaccine agent contains 0.1-1 mg of glycine zinc adjuvant dissolved by a PBS with the pH of 6-8. The glycine zinc adjuvant provided by the invention is a pharmaceutic adjuvant, a zinc nutrition enhancer, less in toxic and side effects, and safe and reliable when being used within the immunizing dose range, and can be used for inducing the humoral immune response with antigenic specificity effectively, and the effect of the induced humoral immune response is superior to the non-adjuvant group, the raw material of the glycine zinc adjuvant is easy to obtain because the glycine zinc adjuvant is a commercial product; the glycine zinc adjuvant has the advantages that the preparation technology is simple, the cost is low, the performance is stable, the biological value is relatively high, and no toxicity is achieved, so that the glycine zinc adjuvant can be used as a vaccine adjuvant to be added into the various conventional vaccines and gene engineering vaccines.

Description

[0001] technical field [0002] The invention relates to a zinc glycine adjuvant and a vaccine containing the adjuvant, belonging to the technical field of immunology. Background technique [0003] In recent years, with the continuous deepening of vaccine research, especially the rapid development of molecular biotechnology, new genetic engineering vaccines have been developed with high purity and strong specificity, but small molecules and relatively weak immunogenicity make it difficult to produce effective immunity. answer. Therefore, it is particularly important to use adjuvants to enhance its immunogenicity. [0004] At present, there are still very few adjuvants that have been approved for use in humans, and aluminum salt adjuvants are one of them. Aluminum salt adjuvants have been proven to improve antibody levels and safety for a long time, but due to their shortcomings such as causing allergies and inducing degenerative neuropathy, there is an urgent need to devel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/39A61P37/04
Inventor 陈振普王海漩胡凝珠胡云章
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap